



(12) **EUROPEAN PATENT APPLICATION**  
published in accordance with Art. 158(3) EPC

(43) Date of publication:  
16.10.2002 Bulletin 2002/42

(51) Int Cl.<sup>7</sup>: **A61K 31/60, A61P 17/04**  
// (A61K9/06, 9:70)

(21) Application number: **00981741.2**

(86) International application number:  
**PCT/JP00/08888**

(22) Date of filing: **15.12.2000**

(87) International publication number:  
**WO 01/047525 (05.07.2001 Gazette 2001/27)**

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU**  
**MC NL PT SE TR**  
Designated Extension States:  
**AL LT LV MK RO SI**

(30) Priority: **28.12.1999 JP 37354799**

(71) Applicant: **TEIKOKU SEIYAKU CO., LTD.**  
**Kagawa 769-2695 (JP)**

(72) Inventors:  
• **INAMOTO, Yukiko**  
**Kagawa-gun, Kagawa 761-1703 (JP)**

- **KAWATA, Mitsuhiko**  
**Okawa-gun, Kagawa 769-2702 (JP)**
- **KAWABATA, Seichiro**  
**Okawa-gun, Kagawa 769-2601 (JP)**
- **NAKAYAMA, Daisuke**  
**Takamatsu-shi, Kagawa 761-0104 (JP)**
- **HISAICHI, Shin-ichi**  
**Kita-gun, Kagawa 761-0612 (JP)**
- **TOKUDA, Masaaki**  
**Takamatsu-shi, Kagawa 761-8071 (JP)**

(74) Representative: **Albrecht, Thomas, Dr. et al**  
**Kraus & Welsert,**  
**Thomas-Wimmer-Ring 15**  
**80539 München (DE)**

(54) **ANTIPRURITIC AGENTS FOR EXTERNAL USE**

(57) External preparations for treating pruritus containing Aspirin as an active ingredient, which exert an excellent therapeutic effects on pruritus with less side effects.

## Description

## Technical Field

5 [0001] The present invention relates to external preparations having an excellent antipruritic activity and a method for treating pruritus. In more detail the present invention relates to external preparations having an excellent antipruritic activity containing acetylsalicylic acid as an active ingredient and a method for treating pruritus by using said external preparations.

## 10 Background Art

[0002] Recently according to change of life style, diseases with strong itching, such as atopic dermatitis, urticaria, skin pruritus, etc. have rapidly increased. Further, sting by insects (bite) often elicits very strong itching.

15 [0003] Nowadays many antipruritic agents such as antihistamines etc. are sold. In case of an oral preparation thereof being taken, it is anxious for its side effects, such as sleepiness, laziness, etc.

[0004] On the other hand an antipruritic activity of an external preparation containing an antihistamine or a nonsteroidal antiinflammatory agent is not satisfactory, and especially the preparation containing an antihistamine is also anxious for its side effects such as dermal anaphylaxis, and the preparation containing a nonsteroidal antiinflammatory agent is also anxious for its side effects, such as dermal irritation, contact dermatitis, etc.

20 [0005] Furthermore, although steroids for an external application which are essential for the therapy of atopic dermatitis, are very useful for eczema, skin pruritus, sting by insects, etc., these steroids are not only anxious for their side effects, such as atrophica cutis, steroid flush, angiotelectasis, etc., when repeatedly taken, but also these steroids are transdermally absorbed to migrate to blood and have a possibility to give systemically bad effects.

25 [0006] Acetylsalicylic acid (Hereinafter it may be written as Aspirin.) has a strong analgesic activity, an antifebrile activity and an antirheumatic activity being less in its side effects and being superior in its safety. Therefore, Aspirin has been widely used from of old.

[0007] Recently there have been the studies for applications of external preparations containing acetylsalicylic acid. As a result a composition being superior in transdermal absorption, a new gel-preparation, a tape preparation and a plaster are disclosed in published patent specifications, etc.

30 [0008] Furthermore, as a new use of acetylsalicylic acid in form of an external preparation, ointments for treating neuralgia (Japanese Patent Pub. A3-72426), external preparations for treating skin injury (Japanese Patent Pub. A9-235232), a transdermal administration system for treatment of thrombosis and for prophylactic treatment of cancer (Japanese Patent Pub. Tokuhyo 8-504198) are illustrated.

35 [0009] However, any external preparation containing Aspirin for treating pruritus and the therapeutic effect thereof have not been reported.

## Disclosure of Invention

40 [0010] The present invention is to provide external preparations which have an excellent antipruritic activity and are less in their side effects.

[0011] The present inventors have earnestly studied and as a result, have found that an external preparation containing acetylsalicylic acid as an active ingredient is less in its side effects and shows an excellent antipruritic activity. Thus the present invention has been completed.

45 [0012] Namely, the present inventors have prepared the external preparation containing acetylsalicylic acid for treating pruritus and when the preparation has been applied to a lesion, for example to the lesion with itching, such as sting by insects, injured skin, eczema, dermal pruritus, atopic dermatitis, etc., the excellent antipruritic effect has been found.

[0013] Acetylsalicylic acid contained in the external preparation of the present invention is described in the Pharmacopoeia of Japan XIII.

50 [0014] The amount of acetylsalicylic acid in the external preparation depends on form of the preparation, but is 0.05-80%, preferably 0.05-70%, more preferably 0.1-50% per total amount by weight. When the amount of acetylsalicylic acid is more than 80% by weight, it is impossible to maintain the physical property as an external preparation. When the amount of acetylsalicylic acid is less than 0.05% by weight, the antipruritic activity by acetylsalicylic acid does not show enough. The amount as more than 80% or less than 0.05% by weight, therefore is not preferable.

55 [0015] Examples of diseases with itching for which the external preparation of the present invention is used are itching with skin diseases, such as atopic dermatitis, eczema, contact dermatitis, seborrheic dermatitis, urticaria, puerile strophulus, sting by insects, dermal pruritus, itching, etc.; senile pruritus; itching with metabolic diseases, such as hepatocirrhosis, uremia, chronic nephritis, etc.; itching with endocrine or dys-hormonic disease such as diabetes; and itching with skin injury, such as cut, wound after operation, or burn.

[0016] The external preparation of the present invention is not limited as far as it is the preparation in which acetylsalicylic acid can be directly applied on the local surface of skin, such as ointments, solutions (e.g. suspensions, emulsions, lotions), cataplasms, tapes, aerosols and external powders (powders for external use).

[0017] As other ingredients of the preparation of the present invention can be used any ingredient used in the ordinarily external preparation.

[0018] In case of ointments, creams, gels and lotions, bases, such as white vaseline (petrolatum), yellow vaseline, lanolin, purified bee wax, cetanol, stearyl alcohol, stearic acid, hydrogenated oil, hydrocarbon gel, polyethylene glycol, liquid paraffin and squalane; solvents or solubilizing agents, such as oleic acid, isopropyl myristate, glycerol triisooctanoate, crotamiton, diethyl sebacate, diisopropyl sebacate, diisopropyl adipate, hexyl laurate, a fatty acid, a fatty acid ester, an aliphatic alcohol, and a plant oil; antioxidants, such as a tocopherol derivative, L-ascorbic acid, dibutylhydroxytoluene and butylhydroxyanisole; antiseptics such as p-hydroxybenzoate; humectants, such as glycerin, propylene glycol and sodium hyaluronate; surfactants, such as a polyoxyethylene derivative, a glycerol fatty acid ester, a sucrose fatty acid ester, a sorbitan fatty acid ester, a propylene glycol fatty acid ester and lecithin; thickening agents, such as carboxyvinyl polymer, xanthan gum, carboxymethyl cellulose, sodium carboxymethyl cellulose, hydroxypropyl cellulose and hydroxypropylmethyl cellulose; stabilizers; preservatives; absorption promoters; and other suitable fillers may be added.

[0019] In case of cataplasms, tackifiers, such as polyacrylic acid and polyacrylic acid copolymer; crosslinkers, such as aluminum sulfate, aluminum potassium sulfate, aluminum chloride, magnesium aluminometasilicate and dihydroxyaluminum aminoacetate; thickening agents, such as sodium polyacrylate, polyvinyl alcohol, polyvinylpyrrolidone, gelatin, sodium alginate, carboxymethyl cellulose, sodium carboxymethyl cellulose, hydroxypropyl cellulose and hydroxypropylmethyl cellulose; polyhydric alcohols, such as glycerin, polyethylene glycol (macrogol), propylene glycol and 1,3-butanediol; surfactants such as a polyoxyethylene derivative; perfumes such as *l*-menthol; antiseptics such as p-hydroxybenzoate; purified water; and other suitable fillers may be added.

[0020] In case of tapes, tacking agents, such as a styrene-isoprene-styrene block copolymer and an acrylate resin; tackifier resins, such as an alicyclic saturated hydrocarbon resin, a hydrogenated rosin resin and a terpene resin; softeners, such as liquid gum and liquid paraffin; antioxidants such as dibutylhydroxytoluene; polyhydric alcohols such as polyethylene glycol; absorption promoters such as oleic acid; surfactants such as a polyoxyethylene derivative; and other suitable fillers may be added. In addition a water-absorbable polymer, such as sodium polyacrylate and polyvinyl alcohol, and a small amount of purified water may be added to prepare tape preparations containing water.

[0021] In case of aerosols, bases, such as white vaseline (petrolatum), yellow vaseline, lanolin, purified bee wax, cetanol, stearyl alcohol, stearic acid, hydrogenated oil, hydrocarbon gel, polyethylene glycol, liquid paraffin and squalane; solvents or solubilizing agents, such as oleic acid, isopropyl myristate, isopropyl adipate, diisopropyl sebacate, glycerol triisooctanoate, crotamiton, diethyl sebacate, hexyl laurate, a fatty acid, a fatty acid ester, an aliphatic alcohol and a plant oil; antioxidants, such as a tocopherol derivative, L-ascorbic acid, dibutylhydroxytoluene and butylhydroxyanisole; antiseptics such as p-hydroxybenzoate; humectants, such as glycerin, propylene glycol and sodium hyaluronate; surfactants, such as a polyoxyethylene derivative, a glycerol fatty acid ester, a sucrose fatty acid ester, a sorbitan fatty acid ester, a propylene glycol fatty acid ester and lecithin; thickening agents, such as carboxyvinyl polymer, xanthan gum, carboxymethyl cellulose, sodium carboxymethyl cellulose, hydroxypropyl cellulose and hydroxypropylmethyl cellulose, as used in the ointments, the creams, the gels, the suspensions, the emulsifying agents or the lotions; stabilizers; buffering agents; sweetening agents; suspending agents; emulsifying agents; flavors; preservatives; solubilizing agents; and other suitable fillers, may be added.

[0022] In case of external powders, fillers, such as potato starch, rice starch, corn starch, talc and zinc oxide, and other suitable additives may be added to them.

[0023] The external preparation of the present invention can be prepared, for example by well kneading each ingredient, if necessary with a suitable base, in accordance with a usual manner to prepare external preparations.

[0024] The amount of acetylsalicylic acid as an active ingredient depends on the preparation, but is 0.05-30% by weight in ointments, creams, gels and lotions, is 0.1-20% by weight in cataplasms, is 5-50% by weight in tapes, and is 10-80% by weight in external powders.

[0025] Thus prepared preparation is applied to the lesion, if necessary.

#### Best Mode for Carrying out Invention

[0026] The external preparations containing acetylsalicylic acid of the present invention are explained by examples and experimental examples, but the present invention is not limited by these examples.

#### Examples 1-10 (Ointments)

[0027] According to ingredients indicated in Table 1, hydrocarbon gel and a solvent (oleic acid, Tween 80, crotamiton,

diisopropyl adipate or isopropyl myristate) were dissolved by warming on a water bath, and thereto was added acetyl-salicylic acid (Aspirin) to dissolve or well disperse under stirring. Then the mixture was cooled under stirring to prepare ointments.

Table 1:

Ingredients of ointments containing Aspirin										
Examples	1	2	3	4	5	6	7	8	9	10
Ingredients	Ingredient ratio (wt%)									
Aspirin	0.1	0.5	2.0	10.0	20.0	2.0	2.0	2.0	2.0	2.0
Oleic acid	-	-	-	-	-	5.0	-	-	-	-
Tween 80	-	-	-	-	-	-	5.0	-	-	-
Crotamiton	-	-	-	-	-	-	-	5.0	-	-
Diisopropyl adipate	-	-	-	-	-	-	-	-	5.0	-
Isopropyl myristate	2.5	2.5	2.5	2.5	2.5	-	-	-	-	5.0
Hydrocarbon gel	97.4	97.0	95.5	87.5	77.5	93.0	93.0	93.0	93.0	93.0

#### Examples 11-15 (Lotions)

[0028] According to ingredients indicated in Table 2, Aspirin was added to a warmed oil layer to dissolve or disperse. Separately other ingredients were dissolved in previously warmed purified water, and the oil layer was added thereto under vigorously stirring. The mixture was been mixing to homogeneity under gradually cooling to prepare lotions.

Table 2:

Ingredients of lotions containing Aspirin					
Examples	11	12	13	14	15
Ingredients	Ingredient ratio (wt%)				
Aspirin	0.5	2.0	10.0	5.0	5.0
Crotamiton	1.0	2.0	5.0	-	-
Isopropanol	-	-	-	2.0	-
Diisopropyl sebacate	-	-	-	-	5.0
Squalane	3.0	3.0	3.0	3.0	3.0
Cetanol	3.0	3.0	3.0	3.0	3.0
Solbitan sesquioleate	0.5	0.5	0.5	0.5	0.5
Polyoxy (20) cetyl ether	1.5	1.5	1.5	1.5	1.5
Propylene glycol	5.0	5.0	5.0	5.0	5.0
Triethanolamine	0.4	0.4	0.4	0.4	0.4
Purified water	85.1	82.6	71.6	79.6	76.6

#### Examples 16-20 (Gels)

[0029] According to ingredients indicated in Table 3, after a water soluble polymer was dissolved on a water bath, Aspirin was dissolved or dispersed in a solvent and these ingredients with other bases were being mixed to homogeneity to prepare gels.

Table 3:

Ingredients of gels containing Aspirin					
Examples	16	17	18	19	20
Ingredients	Ingredient ratio (wt%)				
Aspirin	0.1	2.0	10.0	5.0	5.0
Crotamiton	5.0	5.0	5.0	3.0	-
Isopropanol	-	-	-	3.0	5.0
Propylene glycol	45.0	45.0	45.0	45.0	45.0
Polyacrylic acid	25.0	25.0	25.0	25.0	25.0
Triethanolamine	0.7	0.7	0.7	0.7	0.7
Purified water	24.2	22.3	14.3	18.3	19.3

Examples 21-25 (Creams)

[0030] According to ingredients indicated in Table 4, after a solid base was dissolved on a water bath, Aspirin dissolved or dispersed in a solvent was added thereto. A watersoluble base was dissolved in water and its warmed solution was added to the mixture. The mixture was kneaded until it became homogenous to prepare creams.

Table 4:

Ingredients of ointments containing Aspirin					
Examples	21	22	23	24	25
Ingredients	Ingredient ratio (wt%)				
Aspirin	0.5	2.0	10.0	2.0	2.0
Crotamiton	2.5	2.5	2.5	5.0	-
Sesame oil	-	-	-	-	5.0
Diisopropyl sebacate	2.5	2.5	2.5	-	-
Cetanol	9.0	9.0	9.0	9.0	9.0
White vaseline	8.0	8.0	8.0	8.0	8.0
Hexyldecanol	1.0	1.0	1.0	1.0	1.0
Polyethylene glycol monostearate	2.0	2.0	2.0	2.0	2.0
Polyoxy (9) lauryl ether	2.0	2.0	2.8	2.8	2.8
Polyoxy (23) cetyl ether	2.0	2.0	2.0	2.0	2.0
Propylene glycol	12.0	12.0	12.0	12.0	12.0
Methylparaben	0.1	0.1	0.1	0.1	0.1
Propylparaben	0.1	0.1	0.1	0.1	0.1
Purified water	57.5	56.0	48.0	56.0	56.0

Examples 26-30 (Tapes)

[0031] According to ingredients indicated in Table 5, to a tacking agent consisting of an acrylate resin or a styrene-isoprene-styrene block copolymer were added an alicyclic saturated hydrocarbon resin, liquid paraffin, polybutene, an antioxidant, etc. and the mixture was dissolved in an organic solvent such as toluene etc. under stirring, or the mixture was melted by heating under stirring. Thereto was added Aspirin and the resulting mixture was spread on releasing paper and in case of a solution type, was spread on releasing paper and dried. The releasing paper was laminated on a flexible support to be cut into a desired size to prepare tapes.

Table 5:

Ingredients of tapes containing Aspirin					
Examples	26	27	28	29	30
Ingredients	Ingredient ratio (wt%)				
Aspirin	10.0	30.0	50.0	30.0	30.0
Isopropyl myristate	-	-	-	-	5.0
Diisopropyl adipate	-	-	-	5.0	-
Crotamiton	5.0	5.0	7.0	-	-
Acrylate-vinyl acetate copolymer	-	-	-	-	65.0
Styrene-isoprene-styrene block copolymer	20.0	13.4	7.5	13.4	-
Alicyclic saturated hydrocarbon resin	42.0	23.5	11.7	23.5	-
Polybutene	15.0	11.6	5.6	11.6	-
Liquid paraffin	7.0	15.5	17.2	15.5	-
Dibutyl hydroxytoluene	1.0	1.0	1.0	1.0	-

Examples 31-33 (Cataplasms)

[0032] According to ingredients indicated in Table 6, a tackifier such as a polyacrylic acid etc. and a thickening agents were dissolved under heating in a polyhydric alcohol such as glycerin etc. After cooling, Aspirin and other fillers were blended to homogeneity and thereto was added a crosslinker to prepare an adhesive gel base. The gel base was spread on a suitable support such as a non-woven fabric to be cut in a desired size to prepare cataplasms.

Table 6:

Ingredients of cataplasms containing Aspirin			
Examples	31	32	33
Ingredients	Ingredient ratio (wt%)		
Aspirin	0.5	2.0	10.0
Polyacrylic acid	8.0	8.0	8.0
Sodium polyacrylate	4.0	4.0	4.0
Sodium carboxy cellulose	5.0	5.0	5.0
Tartaric acid	1.6	1.6	1.6
Dihydroxyaluminum aminoacetate	0.07	0.07	0.07
Glycerin	34.5	33.0	25.0
Crotamiton	2.0	2.0	2.0
Sesame oil	1.0	1.0	1.0
Purified water	43.33	43.33	43.33

Examples 34-36 (Powders)

[0033] According to ingredients indicated in Table 7, potato starch, zinc oxide and Aspirin were well mixed to prepare powders.

Table 7:

Ingredients of powders containing Aspirin			
Examples	34	35	36
Ingredients	Ingredient ratio (wt%)		
Aspirin	20.0	40.0	80.0
Potato starch	76.0	56.0	16.0
Zinc oxide	4.0	4.0	4.0

Comparative examples 1-2

[0034] According to the method of preparing ointments, ointments having ingredients of Table 8 (comparative examples 1-2) were prepared.

Table 8:

Ingredients of ointments (Comparative examples)		
Comparative examples	1	2
Ingredients	Ingredient ratio (wt%)	
Diphenhydramine	1.0	-
Dexamethasone	-	0.1
Propylene glycol	10.0	10.0
Isopropyl myristate	5.0	5.0
Hydrocarbon gel	84.0	84.9

[0035] Test [A]: An antipruritic activity was tested by administering the external preparation of the present invention for treating pruritus to patients (volunteers).

[0036] The degree of itching-improvement was evaluated based on the following five steps standard:

- A: Remarkably effective,
- B: Effective,
- C: Slightly effective,
- D: No change,
- E: Worse.

[0037] Being slightly effective (C) or more than slightly effective (A, B), degree was judged to be effective, and its effective rate was calculated.

[0038] In the following experiments 1-4, an ointment containing diphenhydramine having antihistaminic activity (comparative example 1) and an ointment containing dexamethasone (steroid) of comparative example 2 were evaluated, too.

[0039] In experiment 5, an ointment containing isopropyl azulene (0.033%) and purified lanolin and white vaseline as bases, which was commercially available as a therapeutic agent for inflammatory dermatitis (comparative example 3), was used as a comparative example.

Experiment 1: Improvement of itching due to sting by insects on patients

[0040] The external preparations containing Aspirin and the controls were applied to lesions on each patient (total 45 volunteers) with itching due to sting by insects and the degree of improvement of itching was evaluated.

[0041] The result is shown in Table 9.

Table 9:

Degree of improvement of itching due to sting by insects on patients								
Groups	Drugs (wt%)	No. of patient	Evaluation					Effective rate(%)
			A	B	C	D	E	
Ointment base	-	5	0	0	0	4	1	0
Example 1	Asps (0.1)	4	0	0	2	2	0	50.0
Example 3	Aspirin (2)	7	2	3	1	0	1	85.7
Example 4	Aspirin (10)	7	1	3	2	1	0	85.7
Example 5	Aspirin (20)	5	2	2	0	1	0	80.0
Example 29	Aspirin (30)	7	2	2	2	1	0	85.7
Comp. Ex.1	Diphenhydramine(1)	5	1	0	1	3	0	40.0
Comp. Ex.2	Dexamethasone (0.1)	5	1	1	1	2	0	60.0

[0042] As is clear from the result in Table 9, examples 1, 3-5 and 29 containing Aspirin inhibited itching due to sting by insect and showed the same or superior antipruritic effect, comparing with the ointment base and comparative examples 1 and 2.

#### Experiment 2: Degree of improvement of itching due to eczema on patients

[0043] The external preparations containing Aspirin and the controls were applied to lesions on each patient (total 32 volunteers) with itching due to eczema and the degree of improvement of itching was evaluated.

[0044] The result is shown in Table 10.

Table 10:

Degree of improvement of itching due to eczema on patients								
Groups	Drugs (wt%)	No. of patient	Evaluation					Effective rate(%)
			A	B	C	D	E	
Ointment base	-	3	0	0	0	2	1	0
Example 9	Aspirin (2)	6	1	1	1	2	0	60.0
Example 12	Aspirin (2)	6	2	1	2	0	1	83.3
Example 17	Aspirin (2)	4	0	1	2	1	0	75.0
Example 21	Aspirin (0.5)	4	1	1	1	0	1	75.0
Example 33	Aspirin (10)	3	0	1	1	1	0	66.7
Comp. Ex. 1	Diphenhydramine(1)	3	0	1	0	2	0	33.3
Comp. Ex.2	Dexamethasone (0.1)	4	1	0	1	2	0	50.0

[0045] As is clear from the result in Table 10, examples 9, 12, 17, 21 and 33 containing Aspirin more inhibited itching due to eczema and showed a superior antipruritic effect, comparing with the ointment base and comparative examples 1 and 2.

#### Experiment 3: Degree of improvement of itching due to dermal pruritus on volunteers

[0046] The external preparations containing Aspirin and the controls were applied to lesions on each patient (total 31 volunteers) with itching due to dermal pruritus and the degree of improvement of itching was evaluated.

[0047] The result is shown in Table 11.



Table 11:

Degree of improvement of itching due to dermal pruritus on patients								
Groups	Drugs (wt%)	No. of patient	Evaluation					Effective rate(%)
			A	B	C	D	E	
Ointment base	-	3	0	0	0	2	1	0
Example 8	Aspirin (2)	6	0	1	3	1	1	66.7
Example 15	Aspirin (2)	4	1	0	2	1	0	75.0
Example 20	Aspirin (5)	4	0	1	2	1	0	75.0
Example 21	Aspirin (0.5)	3	0	0	2	1	0	66.7
Example 24	Aspirin (5)	3	0	1	1	1	0	66.7
Comp. Ex. 1	Diphenhydramine(1)	4	1	0	1	1	1	50.0
Comp. Ex.2	Dexamethasone (0.1)	4	1	0	1	2	0	50.0

[0048] As is clear from the result in Table 11, examples 8, 15, 20, 21 and 24 containing Aspirin more inhibited itching due to dermal pruritus and showed a superior antipruritic effect, comparing with the ointment base and comparative examples 1 and 2.

#### Experiment 4: Degree of improvement of itching due to allergic dermatitis on patients

[0049] The external preparations containing Aspirin and the controls were applied to lesions on each patient (total 37 volunteers) with itching due to allergic dermatitis and the degree of improvement of itching was evaluated.

[0050] The result is shown in Table 12.

Table 12:

Degree of improvement of itching due to allergic dermatitis on patients								
Groups	Drugs (wt%)	No. of patient	Evaluation					Effective rate(%)
			A	B	C	D	E	
Ointment base	-	3	0	0	0	2	1	0
Example 10	Aspirin (2)	4	0	1	2	1	0	75.0
Example 13	Aspirin (10)	3	0	0	2	0	1	66.7
Example 18	Aspirin (10)	3	0	1	1	1	0	66.7
Example 20	Aspirin (5)	3	0	0	1	0	1	66.7
Example 26	Aspirin (10)	4	1	2	1	1	0	75.0
Example 27	Aspirin (30)	4	0	1	0	2	0	50.0
Example 28	Aspirin (50)	4	1	2	1	1	0	75.0
Comp. Ex. 1	Diphenhydramine(1)	5	0	1	1	2	1	40.0
Comp. Ex.2	Dexamethasone (0.1)	4	0	2	0	2	0	50.0

[0051] As is clear from the result of Table 12, examples 10, 13 and 25-28 containing Aspirin inhibited itching due to allergic dermatitis and showed the same or superior antipruritic effect, comparing with the ointment base and comparative examples 1 and 2.

#### Experiment 5: Degree of improvement of itching due to burns on patients

[0052] The external preparations containing Aspirin and the controls were applied to lesions on each patient (total 18 volunteers) who complained of itching on the process of treating a burn among patients suffering the burn.

[0053] The result is shown in Table 13.

Table 13:

Degree of improvement of itching due to a burn on patients								
Groups	Drugs (wt%)	No. of patient	Evaluation					Effective rate(%)
			A	B	C	D	E	
Ointment base	-	4	0	0	0	3	1	0
Example 4	Aspirin (10.0)	4	1	1	1	1	0	75
Example 9	Aspirin (2.0)	4	0	2	1	1	0	75
Example 21	Aspirin (0.5)	3	1	1	0	1	0	67
Comp. Ex. 3	Dimethyl isopropyl azulene (0.033)	3	0	0	1	3	0	33

[0054] As is clear from the result in Table 13, it was confirmed that examples 4, 9 and 21 containing Aspirin more inhibited itching on the process of treating a burn of the patients, comparing with the ointment base and comparative example 3.

[0055] Test [B]: The exacerbation of infectious diseases as one of side effects of steroids has been often problematic. On the other hand decrease of the barrier function of skin is indicated as one of causal factors of allergic dermatitis. As being understood from the fact that a lot of bacteria are present in normal skin tissue, it is well known that when steroids are administered to patients suffered from allergic dermatitis, infectious diseases are apt to be caused due to decrease of immunogenicity.

[0056] As such, using examples 2 and 5 of the present invention and comparative examples 1 and 2, the decrease of the immunogenicity was evaluated by setting on the reduction of weight of thymus and adrenal gland as an index.

#### Experimental example 6

[0057] In this test Wistar male rats (8 weeks old, 6 rats/group) were used. After removal of hairs on the back, the rats were collared not to lick the tested drug (examples 2, 5 and comparative examples 1, 2) on the back. The tested drug (0.5g/rat/day) was applied to the back in the range of 5cm x 5cm for 7 days. After administration the rat was killed and thymus and adrenal gland were extracted from the rat and their weights were measured.

[0058] The results are shown in Table 14.

Table 14:

Thymus weight and adrenal gland weight administered by each preparation (per body weight (100g))		
Groups	Thymus weight (mg)	Adrenal gland weight (mg)
Non-treated	159±12	20.6±1.0
Ointment base	160±10	19.7±1.3
Example 2	160±7	21.0±0.7
Example 5	162±8	20.0±1.3
Comparative example 1	158±9	18.7±0.7
Comparative example 2	37±2	15.6±1.0
Means ± standard error		

[0059] As shown in Table 14, comparative example 2 much reduced weights of thymus and adrenal gland comparing with examples 2 and 5. The steroid ointment reduced weights of thymus and adrenal gland, one of indexes of immunogenicity, but examples 2 and 5 did not reduce the weights of these organs. Therefore, it is clear that the ointments containing Aspirin of the present invention is less in its side effects and a superior antipruritic agent comparing with the ointment of comparative example 2.

Possibility of Industrial applicability

[0060] The external preparation for treating pruritus of the present invention contains Aspirin as an active ingredient and has an excellent therapeutic effect to itching. Furthermore, the external preparation for treating pruritus of the present invention does not reduce weights of thymus and adrenal gland even by continuous applications and therefore, the preparation of the present invention belongs to the drug showing very little side effects. The present invention can provide the external preparation being not only excellently effective to various itching, but also being very little in its side effects.

Claims

1. An external preparation for treating pruritus containing acetylsalicylic acid as an active ingredient.
2. Use of acetylsalicylic acid as an active ingredient for preparing an external preparation for treating pruritus.
3. A method for treating a patient suffering from pruritus comprising transdermally administering an effective amount of acetylsalicylic acid to the patient.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP00/08888

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> Int.Cl <sup>7</sup> A61K31/60, A61P31/04 // A61K9/06, 9/70  According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) Int.Cl <sup>7</sup> A61K31/60, A61P31/04 // A61K9/06, 9/70  Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAPLUS (STN), MEDLINE (STN), EMBASE (STN)		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JUNGNICKEL P.W. et al., 'Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions.' Journal of General Internal Medicine, 1997, Vol.12, No.10 pages 591 to 596	1-2
X	YOSIPOVITCH G. et al., 'Topically applied aspirin rapidly decreases histamine-induced itch.' Acta Derm.-Venereol., 1997, Vol.77, No.1, pages 46 to 48	1-2
X	US, 5932230, A (DEGRATE, FRENCHELL), 03 August, 1999 (03.08.99) (Family: none) & Database CAPLUS on STN, AMERICAN CHEMICAL SOCIETY (ACS), (Columbus, OH, USA), RN.131:134638	1-2
A	HAGERMARK, Osten, 'Influence of antihistamines, sedatives, and aspirin on experimental itch.' Acta Derm.-Venereol., 1973, Vol.53, No.5, pages 363 to 368	1-2
A	DALEY B.M. et al., 'Effect of aspirin on pruritus.' British Medical Journal, 1986, Vol.293, No.6552,	1-2
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 21 February, 2001 (21.02.01)		Date of mailing of the international search report 06 March, 2001 (06.03.01)
Name and mailing address of the ISA/ Japanese Patent Office		Authorized officer
Facsimile No.		Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)

BEST AVAILABLE COPY

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP00/08888

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	pages 907	
A	JP, 1-29315, A (Tokyo Medikku), 31 January, 1989 (01.31.89) (Family: none) & Database CAPLUS on STN, AMERICAN CHEMICAL SOCIETY (ACS), (Columbus, OH, USA), RN.111:102758	1-2

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

BEST AVAILABLE COPY

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP00/08888

**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 3  
because they relate to subject matter not required to be searched by this Authority, namely:  
Claim 3 pertains to methods for treatment of the human body by therapy and thus relates to a subject matter which this International Searching Authority is not required, under the provisions of Article 17(2)(a)(i) of the PCT and Rule 39.1(iv) of the Regulations under the PCT, to search.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1992)

BEST AVAILABLE COPY